Cargando…
The original sins of clinical trials with intravenous immunoglobulins in sepsis
Intravenous immunoglobulins (IVIGs) have not yet demonstrated robust evidence in the benefit for treatment of sepsis. In spite of multiple clinical trials performed with IVIG in sepsis, it remains an experimental therapy for this severe condition. Nonetheless, these trials do not address a number of...
Autores principales: | Almansa, Raquel, Tamayo, Eduardo, Andaluz-Ojeda, David, Nogales, Leonor, Blanco, Jesús, Eiros, Jose Maria, Gomez-Herreras, Jose Ignacio, Bermejo-Martin, Jesus F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4343266/ https://www.ncbi.nlm.nih.gov/pubmed/25882822 http://dx.doi.org/10.1186/s13054-015-0793-0 |
Ejemplares similares
-
Immunological monitoring to prevent and treat sepsis
por: Almansa, Raquel, et al.
Publicado: (2013) -
Quantification of IgM molecular response by droplet digital PCR as a potential tool for the early diagnosis of sepsis
por: Tamayo, Eduardo, et al.
Publicado: (2014) -
Composed endotypes to guide antibiotic discontinuation in sepsis
por: Bermejo-Martin, Jesus F., et al.
Publicado: (2019) -
Superior accuracy of mid-regional proadrenomedullin for mortality prediction in sepsis with varying levels of illness severity
por: Andaluz-Ojeda, David, et al.
Publicado: (2017) -
Early natural killer cell counts in blood predict mortality in severe sepsis
por: Andaluz-Ojeda, David, et al.
Publicado: (2011)